An Inventisbio Co. Ltd. and Inventisbio LLC patent discloses new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Asieris Pharmaceuticals Co. Ltd. has synthesized new protein arginine N-methyltransferase 5 (PRMT5) inhibitors described as potentially useful for the treatment of bladder cancer.
Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic diseases, cardiovascular, inflammatory and immunological disorders.
Several Gluetacs Therapeutics (Shanghai) Co. Ltd. patents describe molecular glue degraders reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.
The med tech patent wars conscripted another two companies via a patent infringement lawsuit between Inari Medical Inc. and Imperative Care Inc. — a struggle that is playing out in a California district court.
Muna Therapeutics ApS has disclosed new potassium voltage-gated channel subfamily A member 3 (KCNA3, Kv1.3) channel blockers reported to be useful for the treatment of cancer, neurodegeneration, cardiovascular, gastrointestinal, immunological, inflammatory, metabolic and renal disorders, among others.
Enanta Pharmaceuticals Inc. has discovered mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis, pulmonary arterial hypertension, irritable bowel syndrome, inflammatory, dermatological and respiratory disorders, among others.
The Brigham and Women's Hospital Inc., Massachusetts General Hospital and UCL Business Ltd. have jointly patented new benzo[c][l,2,5]thiadiazolyl compounds and radiolabeled derivatives targeting α-synuclein, amyloid-β (Aβ) protein and microtubule-associated protein tau.
Work at Greenstone Biosciences Inc. has led to the identification of dihydroartemisinin derivatives reported to be useful for the treatment of fibrosis.
RSS
